- Policy
- There's plenty of COVID-19 PO medicine, Regkirona
- by Lee, Jeong-Hwan Feb 16, 2022 05:51am
- The quarantine authorities said they have secured sufficient supplies of COVID-19 oral treatments in Korea and will continue to consider additional purchases depending on the quarantine situation. The quarantine authorities also said they would consider using the budget for purchasing Regkirona as an oral drug as Regkirona, an antibody treatm
- Company
- The paradox of COVID-19
- by Kim, Jin-Gu Feb 15, 2022 05:54am
- In contrast to the intensifying supply and demand difficulties of cold medicine and the decline in the performance of respiratory Rx drugs such as antibiotics and expectorants. After the transition to COVID-19 home treatment, the shortage phenomenon intensified, and the pharmaceutical industry began to "excess production." Demand for OTC cold m
- Company
- Drug pricing negotiations for ‘Xospata’ complete
- by Eo, Yun-Ho Feb 15, 2022 05:54am
- The new leukemia drug ‘Xospata’ has crossed the final barrier to reimbursement in Korea. According to industry sources, Astellas Pharma Korea completed drug pricing negotiations for its acute myeloid leukemia (AML) treatment Xospata (gilteritinib) with the National Health Insurance Service. Accordingly, if the agenda passes the Healt
- Company
- The next Saxenda? Companies race to occupy GLP-1 RA market
- by Feb 15, 2022 05:54am
- GLP-1 class drugs are taking over the obesity treatment market. With ‘Saxenda’ in the lead, pharmaceutical companies in Korea and abroad are racing to catch up with Novo Nordisk, while the company is working to bring another improved GLP-1 analogue into the market. According to industry sources on the 14th, pharmaceutical companies in Korea
- Company
- Takeda, Boehringer, & AZ were selected as the Best Companies
- by Eo, Yun-Ho Feb 15, 2022 05:53am
- .Three Korean subsidiaries have been selected as the 2022 Global Top Employment Company. Boeringer Ingelheim, and AstraZeneca Korea were selected as "the best hiring companies" by setting extraordinary efforts and examples for welfare and employee competency development. Among them, Takeda was listed by Korean subsidiaries for the sixth conse
- Company
- Changes in sales and marketing of companies
- by Moon, sung-ho Feb 15, 2022 05:53am
- As the COVID-19 pandemic continues for more than three years, changes are also taking place in academic sales and marketing of pharmaceutical companies. Pharmaceutical companies are competitively holding events for doctors on a rich theme and scale comparable to academic conferences of medical associations. This is a self-rescue measure due to t
- Company
- The era of personalized healthcare has arrived
- by Eo, Yun-Ho Feb 14, 2022 05:54am
- Optimal treatment for each patient differs by one’s genetic mutation. With this discovery, anticancer therapies targeting individualized genes have emerged one after another, and the field of precision medicine is evolving from ‘disease-targeted’ to ‘gene-targeted’ prescriptions. In particular, anticipation in the field is rising wit
- Opinion
- [Reporter's view]Predictability should be increased
- by Lee, Tak-Sun Feb 14, 2022 05:54am
- Starting with Choline Alfoscerate, a brain function improving agent, the benefit reassessment, which has been in full swing since last year, has risen again this year. On the 11th, HIRA's Drug Reimbursement Evaluation Committee confirmed the items subject to salary revaluation in 2022 and 2023. Detailed items will be released through the Heal
- Policy
- High-dose ‘pyridoxine’ to be classified as an Rx drug
- by Lee, Hye-Kyung Feb 14, 2022 05:54am
- The high-dose Vitamin B6 ‘Pyridoxine Hydrochloride 300mg’ is likely to be classified as a prescription drug. Although pyridoxine doses up to 250mg are classified as a health functional food abroad, experts reached a consensus that the 300mg dose of the same drug should be classified as a prescription drug in consideration of the side e
- Company
- Saxenda is also effective for childhood obesity
- by Feb 14, 2022 05:54am
- Saxenda of Novonodisc, a drug that can be used in children and adolescents, has emerged as an option for the first time. Effective weight loss is expected to help treat obesity in children and adolescents, but the fact that there is little data on Koreans should be supplemented. Novonodisc held a " Saxenda expansion of Pediatric Adaptation
